MSD to acquire Cidara

Summary by AI BETAClose X

hVIVO plc announced that its client, Cidara Therapeutics, Inc., has entered into an agreement for MSD to acquire Cidara for approximately $9.2 billion, a transaction underscoring hVIVO's role in accelerating drug development. hVIVO provided critical data for Cidara's lead candidate, CD388, an antiviral agent, through a human challenge study in 2023 and a large-scale Phase IIb field study over the 2024/2025 flu season, where hVIVO enrolled 817 participants, the highest number globally. hVIVO also served as the central Virology Laboratory for both Phase IIb and Phase III programs, managing logistics and performing assays, with all primary and secondary endpoints met in the Phase IIb study.

Disclaimer*

Companies

Hvivo (HVO)
UK 100

Latest directors dealings